Replies to post #417537 on NorthWest Biotherapeutics Inc (NWBO)

[Know-Fear]

I was responding to ex’s quote below which was my source for “about 16”. Doing so while on a campus visit with my son. I would agree with your assertion. And will review the patent accordingly when time permits.

The patent is specifically for a "method B DCVax-Direct" that is matured for about 16 hours (they disallowed 12-20) using a sauce that includes the BCG vaccine. It has nothing at to do with with DCVax-L.

[Know-Fear]

Smokey, See claims one and two for the patent pasted below for about 16 hours as the allowed claims

Claims
1. A method for producing isolated partially mature and optimally activated human dendritic cells, comprising:

i) isolating a cell population comprising human PBMCs from peripheral blood;
ii) enriching the cell population comprising human PBMCs for human monocytic dendritic cell precursors;
iii) culturing the cell population enriched for human monocytic dendritic cell precursors with a tissue culture medium supplemented with an effective amount of a dendritic cell differentiation agent for a time period sufficient to differentiate the human monocytic dendritic cell precursors into immature human dendritic cells;
iv) culturing the cell population enriched for immature human dendritic cells with an effective amount of heat inactivated Bacillus Calmette-Guerin (BCG) and Interferon ? (IFN?) as a dendritic cell maturation agent to activate the immature human dendritic cells for about 16 hours without contact with an antigen; and
v) isolating and washing the activated human dendritic cells.

2. A method for producing isolated partially mature and activated human dendritic cells, comprising:

i) isolating a cell population comprising human monocytic dendritic cell precursors;
ii) culturing the cell population enriched for human monocytic dendritic cell precursors with a tissue culture medium supplemented with an effective amount of a dendritic cell differentiation agent for a time period sufficient to differentiate the human monocytic dendritic cell precursors into immature human dendritic cells;
iii) culturing the cell population enriched for immature human dendritic cells with an effective amount of heat inactivated Bacillus Calmette-Guerin (BCG) and Interferon ? (IFN?) as a dendritic cell maturation agent to activate the immature human dendritic cells for about 16 hours without contact with an antigen; and
iv) isolating and washing the activated human dendritic cells.